[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20200336A1 - Formulaciones a largo plazo - Google Patents

Formulaciones a largo plazo

Info

Publication number
PE20200336A1
PE20200336A1 PE2020000033A PE2020000033A PE20200336A1 PE 20200336 A1 PE20200336 A1 PE 20200336A1 PE 2020000033 A PE2020000033 A PE 2020000033A PE 2020000033 A PE2020000033 A PE 2020000033A PE 20200336 A1 PE20200336 A1 PE 20200336A1
Authority
PE
Peru
Prior art keywords
long
pharmaceutical compositions
term formulations
formulations
term
Prior art date
Application number
PE2020000033A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Maristella Bernini
Esther Dina Guido Basstanie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20200336A1 publication Critical patent/PE20200336A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion se refiere a composiciones farmaceuticas para la administracion por via intramuscular o inyeccion subcutanea, que comprende micro o nanoparticulas del compuesto bedaquilina anti-TB, suspendido en un vehiculo acuoso farmaceuticamente aceptable, y al uso de tales composiciones farmaceuticas en el tratamiento y profilaxis de una infeccion por micobacterias patogenas.
PE2020000033A 2017-07-14 2018-07-13 Formulaciones a largo plazo PE20200336A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181354 2017-07-14
EP18167463 2018-04-16
PCT/EP2018/069066 WO2019012100A1 (en) 2017-07-14 2018-07-13 EXTENDED ACTION FORMULATIONS

Publications (1)

Publication Number Publication Date
PE20200336A1 true PE20200336A1 (es) 2020-02-14

Family

ID=62874924

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000033A PE20200336A1 (es) 2017-07-14 2018-07-13 Formulaciones a largo plazo

Country Status (27)

Country Link
US (2) US11141384B2 (es)
EP (3) EP3651736B1 (es)
JP (3) JP7102500B2 (es)
KR (2) KR20240108542A (es)
CN (2) CN115252548A (es)
AU (1) AU2018298855B2 (es)
BR (1) BR112020000687A2 (es)
CA (1) CA3069069A1 (es)
CO (1) CO2020000328A2 (es)
CY (1) CY1124782T1 (es)
DK (2) DK3943070T3 (es)
ES (2) ES2891976T3 (es)
FI (1) FI3943070T3 (es)
HR (2) HRP20240058T1 (es)
HU (2) HUE055762T2 (es)
JO (1) JOP20200004B1 (es)
LT (2) LT3943070T (es)
MD (1) MD3651736T2 (es)
PE (1) PE20200336A1 (es)
PH (1) PH12020500076A1 (es)
PL (2) PL3943070T3 (es)
RS (2) RS62362B1 (es)
SA (1) SA520410975B1 (es)
SI (2) SI3943070T1 (es)
UA (1) UA126403C2 (es)
WO (1) WO2019012100A1 (es)
ZA (1) ZA202000215B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
WO2022008645A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
EP4178540A1 (en) 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Long-acting formulations
PE20231296A1 (es) * 2020-07-09 2023-08-22 Janssen Pharmaceutica Nv Formulaciones a largo plazo
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
TW202423427A (zh) 2022-09-28 2024-06-16 比利時商健生藥品公司 長效配方
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL222801B1 (pl) 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
PT1888604E (pt) 2005-05-25 2012-05-28 Janssen Pharmaceutica Nv Processo para preparar (alfa s, beta r)-6-bromo-alfa-[2- (dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil- 3-quinolinoetanol
WO2007147882A2 (en) * 2006-06-23 2007-12-27 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278
BR112013026363B1 (pt) 2011-04-15 2021-10-13 Janssen Pharmaceutica Nv Nanossuspensões compreendendo 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil] amino] benzonitrila, seu processo de preparação e composição farmacêutica para administração por injeção intramuscular ou subcutânea
JP7291458B2 (ja) * 2015-01-27 2023-06-15 ヤンセン ファーマシューティカ エヌ．ベー． 分散性組成物
US10653679B2 (en) * 2015-05-04 2020-05-19 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
EP3634583A4 (en) 2017-06-06 2021-03-03 Merck Sharp & Dohme Corp. LONG-ACTION IMPLANT FOR THE TREATMENT OF INFECTIOUS DISEASES

Also Published As

Publication number Publication date
EP4356968A2 (en) 2024-04-24
JOP20200004B1 (ar) 2023-09-17
HRP20240058T1 (hr) 2024-03-29
CN115252548A (zh) 2022-11-01
JP7102500B2 (ja) 2022-07-19
JP2024038043A (ja) 2024-03-19
SI3943070T1 (sl) 2024-03-29
AU2018298855A1 (en) 2020-01-16
DK3943070T3 (da) 2024-01-22
JOP20200004A1 (ar) 2020-01-14
ES2970801T3 (es) 2024-05-30
ZA202000215B (en) 2021-07-28
SA520410975B1 (ar) 2022-07-16
KR102679979B1 (ko) 2024-06-28
BR112020000687A2 (pt) 2020-07-14
RS62362B1 (sr) 2021-10-29
EP3651736A1 (en) 2020-05-20
RS65207B1 (sr) 2024-03-29
LT3651736T (lt) 2021-10-11
HRP20211450T1 (hr) 2022-01-07
CY1124782T1 (el) 2022-11-25
PH12020500076A1 (en) 2020-11-09
AU2018298855B2 (en) 2024-07-18
EP3651736B1 (en) 2021-06-23
FI3943070T3 (fi) 2024-01-24
LT3943070T (lt) 2024-02-12
US20210085620A1 (en) 2021-03-25
US20220047522A1 (en) 2022-02-17
CO2020000328A2 (es) 2020-01-31
MD3651736T2 (ro) 2021-12-31
HUE055762T2 (hu) 2021-12-28
HUE064651T2 (hu) 2024-04-28
CN110869004A (zh) 2020-03-06
US11141384B2 (en) 2021-10-12
EP3943070B1 (en) 2023-11-22
EP4356968A3 (en) 2024-07-10
UA126403C2 (uk) 2022-09-28
DK3651736T3 (da) 2021-09-27
JP2020526538A (ja) 2020-08-31
JP7441276B2 (ja) 2024-02-29
PL3943070T3 (pl) 2024-05-06
CA3069069A1 (en) 2019-01-17
PL3651736T3 (pl) 2021-12-20
KR20240108542A (ko) 2024-07-09
ES2891976T3 (es) 2022-02-01
JP2022130709A (ja) 2022-09-06
EP3943070A1 (en) 2022-01-26
WO2019012100A1 (en) 2019-01-17
KR20200028964A (ko) 2020-03-17
SI3651736T1 (sl) 2021-11-30
CN110869004B (zh) 2022-06-14

Similar Documents

Publication Publication Date Title
PE20200336A1 (es) Formulaciones a largo plazo
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
UY30431A1 (es) Suspensiones acuosas de tmc278
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CO2019001044A2 (es) Composición de cannabis
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
CO2017010065A2 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina
CO2023001340A2 (es) Formulaciones a largo plazo
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
CR20170604A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant